2011 AAHA canine vaccination guidelines

Journal of the American Animal Hospital Association

Volumn 47, Issue 5, 2011, Pages 1-42

  Welborn, Link V ^a   DeVries, John G ^a   Ford, Richard ^a   Franklin, Robert T ^a   Hurley, Kate F ^a   McClure, Kent D ^a   Paul, Michael A ^a   Schultz, Ronald D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; PRACTICE GUIDELINE; STANDARD; UNITED STATES; VACCINATION; VETERINARY MEDICINE;

ANIMALS; DOG DISEASES; DOGS; UNITED STATES; VACCINATION; VETERINARY MEDICINE;

EID: 81555209904     PISSN: 05872871     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/JAAHA-MS-4000     Document Type: Article

References (82)

1. Greene CE, Schultz RD. Immunoprophylaxis and immunotherapy. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. Philadelphia: WB Saunders; 2006:1069-119.
2. Pardo MC, Bauman JE, Mackowiak M. Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins. Am J Vet Res 1997;58(8):833-6.
3. Horzinek MC, Schijns VEC, Denis M, et al. General description of vaccines. In: Pastoret PP, Blancou I, Vannier P, et al, eds. Veterinary Vaccinology. Amsterdam: Elsevier; 1997:131-52.
4. Roth JA, Henderson LM. New technology for improved vaccine safety and efficacy. Vet Clin North Am Food Anim Pract 2001;17(3):585-97, vii.
5. Edelman R. 2000. Vaccine adjuvants: Preparation methods and research protocols. In: O'Hagan DT (ed). Clifton, NJ: Humana Press; 2000:1-28.
6. Spickler AR, Roth JA. Adjuvants in veterinary vaccines: Modes of action and adverse effects. J Vet Intern Med 2003;17(3):273-81.
7. Roth JA. Mechanistic bases for adverse vaccine reactions and vaccine failures. In: Schultz RD, ed. Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics. San Diego: Academic Press; 1999:681-700.
8. Dodds WJ. More bumps on the vaccine road. In: Schultz RD, ed. Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics. Vol 41. San Diego: Academic Press; 1999:715-32.
9. Hogenesch H, Azcona-Olivera J, Scott-Moncrieff C, et al. Vaccineinduced autoimmunity in the dog. In: Schultz RD, ed. Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics. Vol 41. San Diego: Academic Press; 1999:733-44.
10. Greene CE, Schultz RD, Ford RB. Canine vaccination. Vet Clin North Am Small Anim Pract 2001;31(3):473-92, v-vi.
11. Ford RB and Schultz RD. Vaccines and vaccination programs for the 21st century. In: Bonagura JD, ed. Kirk's Current Veterinary Therapy XIII. Philadephia: WB Saunders CO; 2000:250-3.
12. Frana TS, Elsken LA, Karli SA. Summary of adverse event reports for veterinary biologic products received by the USDA from 1999 through 2005. J Am Vet Med Assoc 2006;229(7):1100-2.
13. Frana TS, Clough NE, Gatewood DM, et al. Postmarketing surveillance of rabies vaccines for dogs to evaluate safety and efficacy. J Am Vet Med Assoc 2008;232(7):1000-2.
14. Schultz RD. Considerations in designing effective and safe vaccination programs for dogs. In: Carmichael, LE, ed. Recent Advances in Canine Infectious Diseases. International Veterinary Information Service. 2000. Available at: http://www.ivis.org/. Accessed August 2011.
15. Martinod S. In: Pastoret PP, et al. In: Pastoret P, Blancou J, Vannier P, Verschueren C, eds. Adverse Effects of Vaccination in Veterinary Vaccinology. Amsterdam: Elsevier; 1997:574-80.
16. Meyer EK. Vaccine-associated adverse events. Vet Clin N Am. Small Anim Prac. 2001;31:493-514.
17. Phillips TR, Jensen JL, Rubino MJ, et al. Effects of vaccines on the canine immune system. Can J Vet Res 1989;53(2):154-60.
18. Moore GE, Frana TS, Guptill LF, et al. Postmarketing surveillance for dog and cat vaccines: new resources in changing times. J Am Vet Med Assoc 2005a;227(7):1066-9.
19. Carmichael LE. Vaccines for dogs. In: Pastoret P, Blancou J, Vannier P, Verschueren C, eds. Veterinary Vaccinology. Amsterdam: Elsevier; 1997:326-35.
20. Carmichael LE. Canine viral vaccines at a turning point-a personal perspective. In: Schultz RD, ed. Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics. San Diego: Academic Press; 1999:289-307.
21. Schultz RD, Appel MJ, Carmichael LE. Canine vaccines and immunity. In: Kirk RW, ed. Current Veterinary Therapy VI. Philadelphia: WB Saunders Co; 1977:1271-5.
22. Schultz RD. Theory and practice of immunization. In: Kirk RW, ed. Current 285 Veterinary Therapy VII. Philadelphia: W.B. Saunders Co.; 1980:1248-51.
23. Schultz RD, Scott FW. Canine and feline immunization. Vet Clin North Am 1978;8(4):755-68.
24. Schultz R. Current and future canine and feline vaccination programs. Vet Med 1998;93:233-54.
25. Schultz RD, Conklin S. The immune system and vaccines. Compend Contin Educ Pract Vet 1998;20:5-18.
26. Day MJ, Horzinek MC, Schultz RD; Vaccination Guidelines Group. WSAVA guidelines for the vaccination of dogs and cats. J Small Anim Pract 2010;51(6):1-32.
27. Eschner A. Guide for dogs who are late in receiving their regularly scheduled Lyme vaccination. Technical Service Bulletin. Duluth, GA: Merial Limited; 2008.
28. Lehar C, Jayappa H, Erskine J, et al. Demonstration of 1-year duration of immunity for attenuated Bordetella bronchiseptica vaccines in dogs. Vet Ther 2008;9(4):257-62.
29. Jacobs AA, Theelen RP, Jaspers R, et al. Protection of dogs for 13 months against Bordetella bronchiseptica and canine parainfluenza virus with a modified live vaccine. Vet Rec 2005;157(1):19-23.
30. Appel M. Canine distemper virus. In: Appel M, ed. Virus Infections of Carnivore. NY: Elsevier; 1987:133-59.
31. Appel MJ. Forty years of canine vaccination. In: Schultz RD, ed. Advances in Veterinary Medicine 41: Veterinary Vaccines and Diagnostics. Vol 41. San Diego: Academic Press; 1999:309-24.
32. Day MJ, Horzinek MC, Schultz RD; Vaccination Guidelines Group (VGG) of theWorld Small Animal Veterinary Association (WSAVA); Compiled by the Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA). Guidelines for the vaccination of dogs and cats. J Small Anim Pract 2007;48(9):528-41.
33. Povey RC, Carman PS. In: Pastoret PP, et al. Pastoret P, Blancou J, Vannier P, Verschueren C, eds. Technical Basis of Vaccination in Veterinary Vaccinology. Amsterdam: Elsevier; 1997:519-34
34. Chappuis G. Control of canine distemper. Vet Microbiol 1995;44 (2-4):351-8.
35. Audonnet J-C, Minke J, Poulet H. Veterinary applications of the canarypox vaccine vector technology-recent developments for vaccines in domestic mammalian species. In: Moingeon P, ed. Vaccines: Frontiers in Design and Development. Wymondham. Norfolk, UK: Horizon Bioscience; 2005:133-40.
36. Pastoret PP, Vanderplasschen A. Poxviruses as vaccine vectors. Comp Immunol Microbiol Infect Dis 2003;26(5-6):343-55.
37. Hageny TL, Haase CJ, Larson LJ, et al. A comparison between recombinant, naked DNA and modified live canine distemper virus (CDV) vaccines. Dept Pathobiological Sciences, UW Madison School of Vet Med, Madison, WI. Poster Presentation abstract 65: Conference of Workers in Animal Disease, November 13-16, 2004. Chicago, IL.
38. Larson L, Schultz RD. Effect of vaccination with rCDV vaccine immediately before exposure under shelter-like conditions. Vet Ther 2006;7(2):113-8.
39. Larson LJ, Quesada M, et al. Evaluation of a CPV-2 fecal parvovirus ELISA (SNAP fecal parvo test) from IDEXX laboratories. Poster 113. In: Proceedings of Conference of Research Workers in Animal Disease. Chicago, IL; Dec 2-4, 2007.
40. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther 2008;9(2):94-101.
41. Hong C, Decaro N, Desario C, et al. Occurrence of canine parvovirus type 2c in the United States. J Vet Diagn Invest 2007;19(5):535-9.
42. Schultz R., Larson L.. Current canine parvovirus type 2 (CPV-2) vaccines provide excellent immunity to all genotypes of CPV-2 (eg CPV-2a, 2b, and 2c). Presented at Conference for Research Workers in Animal Diseases. Dec 7-9, 2008. Chicago, IL.
43. Schultz RD, Thiel B, Mukhtar E, et al. Age and long-term protective immunity in dogs and cats. J Comp Pathol 2010;142(Suppl 1):S102-8.
44. Spibey N, Greenwood NM, Sutton D, et al. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol 2008;128(1-2):48-55.
45. Schultz RD, Appel MJ, Carmichael LE. Canine vaccines and immunity. In: Kirk RW, ed. Current Veterinary Therapy VI. Philadelphia: WB Saunders Co.; 1977:1271-5.
46. Larson LJ, Hageny TL, Haase CJ, et al. Effect of recombinant canine distemper vaccine on antibody titers in previously vaccinated dogs. Vet Ther 2006;7(2):107-12.
47. Pardo MC, Tanner P, Bauman J, et al. Immunization of puppies in the presence of maternally derived antibodies against canine distemper virus. J Comp Pathol 2007;137(Suppl 1):S72-5.
48. Reed TL, von Messling V, et al. A comparative study of canine distemper vaccines. Poster 87. In: Proceedings of Conference of Research Workers in Animal Disease, Dec 9-11, 2003.
49. Schultz RD, Appel MJ, Carmichael LE. Update on canine immunizations. In: Kirk RW, ed. Canine Veterinary Therapy VII. Philadelphia: WB Saunders Co.; 1980:1252-5.
50. Shroeder JP, Bordt DW, et al. Studies of canine distemper immunization of puppies in a canine distemper-contaminated environment. Vet Med/Small Anim Clin. 1967;62(8):782-7.
51. Larson LJ, Newbury S, Schultz RD. Canine and feline vaccinations and immunology. In: Miller L, Hurley KF, eds. Infectious Disease Management in Animal Shelters. Ames, Iowa: Wiley-Blackwell; 2009:61-82.
52. Larson LJ, Sawchuck S, Schultz RD. 2002. Duration of vaccinal immunity in a population of clinic dogs [abstract 75P]. In: Proceedings 83rd Meeting, Conference Research Workers in Animal Disease. Nov 10-12, 2002. St. Louis, MO.
53. Larson LJ and Schultz RD. Current canine parvovirus type 2 (CPV-2) vaccines provide excellent immunity to genotypes of CPV-2 (eg CPV-2, 2a, 2b, 2c). Conference of Research Workers in Animal Disease. Chicago IL: Dec 2-4, 2007.
54. Schultz RD. Duration of immunity for canine and feline vaccines: a review. Vet Microbiol 2006;117(1):75-9.
55. Gill M, Srinivas J, Morozov I, et al. Three-year duration of immunity for canine distemper, adenovirus, and parvovirus after vaccination with a multivalent canine vaccine. J Appl Res Vet Med 2004; 2(4):227-34.
56. Larson LJ, Schultz RD. Three-year duration of immunity in dogs vaccinated with a canarypox-vectored recombinant canine distemper virus vaccine. Vet Ther 2007a;8(2):101-6.
57. Larson LJ, Schultz RD. Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine. Vet Ther 2007b; 8(4):305-10.
58. Mansfield PD. Vaccination of dogs and cats in veterinary teaching hospitals in North America. J Am Vet Med Assoc 1996;208(8):1242-7.
59. Mouzin DE, Lorenzen MJ, Haworth JD, et al. Duration of serologic response to five viral antigens in dogs. J Am Vet Med Assoc 2004; 224(1):55-60.
60. Olson P, Klingeborn B, Hedhammar A. Serum antibody response to canine parvovirus, canine adenovirus-1, and canine distemper virus in dogs with known status of immunization: study of dogs in Sweden. Am J Vet Res 1988;49(9):1460-6.
61. Olson P, Finnsdóttir H, Klingeborn B, et al. Duration of antibodies elicited by canine distemper virus vaccinations in dogs. Vet Rec 1997; 141(25):654-5.
62. Phillips TR, Schultz RD. Canine and feline vaccines. In: Kirk RW, Bonagura JD, eds. Current Veterinary Therapy XI. Philadelphia: W.B. Saunders Co.; 1992:202-6.
63. Prydie J. Persistence of antibodies following vaccination against canine distemper and the effect of re-vaccination. Vet Rec 1966; 78(14):486-8.
64. Rikula U, Nuotio L, Sihvonen. Canine distemper virus neutralizing antibodies in vaccinated dogs. Vet Rec. 2000;147:598-603.
65. Schultz R and Scott F. Canine and Feline Immunization. Vet Clin N Am 1978;8(4):755-8.
66. Twark L, Dodds WJ. Clinical use of serum parvovirus and distemper virus antibody titers for determining revaccination strategies in healthy dogs. J Am Vet Med Assoc 2000;217(7):1021-4.
67. Schultz RD, Ford RB, Olsen J, et al. Titer testing and vaccination: a new look at traditional practices. Vet Med 2002;97(2):1-13.
68. Guo Y, German T, Schultz RD. Canine parvovirus (CPV-2) antigen expression in plants. Conference of Research Workers in Animal Disease. St. Louis, MO: Nov 11-13, 2001.
69. Abdelmagid OY, Larson L, Payne L, et al. Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges. Vet Ther 2004;5(3):173-86.
70. Aubert MF. Practical significance of rabies antibodies in cats and dogs. Rev Sci Tech 1992;11(3):735-60.
71. Cliquet F, Aubert M, Sagné L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabiesneutralising antibody. J Immunol Methods 1998;212(1):79-87.
72. Cliquet F, Verdier Y, Sagné L, et al. Neutralising antibody titration in 25,000 sera of dogs and cats vaccinated against rabies in France, in the framework of the new regulations that offer an alternative to quarantine. Rev Sci Tech 2003;22(3):857-66.
73. Moore GE, Guptill LF, Ward MP, et al. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc 2005b;227(7):1102-8.
74. Newbury S, Larson LJ, Schultz RD. Canine Distemper Virus. In: Miller L, Hurley KF, eds. Infectious Disease Management in Animal Shelters. Ames, IA: Wileyand Blackwell; 2009:161-73.
75. Ford RB. Canine infectious tracheobronchitis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. Philadelphia: WB Saunders Co.; 2006:54-61.
76. Ford RB. Bordetella bronchiseptica: beyond "kennel cough." In: Bonagura J, Twedt DC, eds. Kirk's Current Veterinary Therapy XIV. St. Louis: Saunders-Elsevier, 2009;647-50.
77. Gore T, Headley M, Laris R, et al. Intranasal kennel cough vaccine protecting dogs from experimental Bordetella bronchiseptica challenge within 72 hours. Vet Rec 2005;156(15):482-3.
78. Deshpande MS, Jirjis FF, Tubbs AL, et al. Evaluation of the efficacy of a canine influenza virus (H3N8) vaccine in dogs following experimental challenge. Vet Ther 2009;10(3):103-12.
79. Crawford C, Spindel M. Canine influenza. In: Miller L, Hurley K, eds. Infectious Disease Management in Animal Shelters. Hoboken, NJ: Wiley-Blackwell; 2009:173-80.
80. Davis R, Jayappa H, Abdelmagid OY, et al. Comparison of the mucosal immune response in dogs vaccinated with either an intranasal avirulent live culture or a subcutaneous antigen extract vaccine of Bordetella bronchiseptica. Vet Ther 2007;8(1):32-40.
81. Ford RB. Vaccination strategies in the shelter environment. In: Miller L, Zawistowski S, eds. Shelter Medicine for Veterinarians and Staff. Ames, IA: Blackwell; 2004:285-304.
82. Jacobs AA, Bergman JG, Theelen RP, et al. Compatibility of a bivalent modified-live vaccine against Bordetella bronchiseptica and CPiV, and a trivalent modified-live vaccine against CPV, CDV and CAV-2. Vet Rec 2007;160(2):41-5.